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The goal of this study was to determine and compare the effects of the secretome of mesenchymal stem cells (MSCs) isolated from
human bone-marrow (BMSCs) and the Wharton jelly surrounding the vein and arteries of the umbilical cord (human umbilical
cord perivascular cells (HUCPVCs)) on the survival and differentiation of a human neuroblastoma cell line (SH-SY5Y). For this
purpose, SH-SY5Y cells were differentiated with conditioned media (CM) from the MSCs populations referred above. Retinoic
acid cultured cells were used as control for neuronal differentiated SH-SY5Y cells. SH-SY5Y cells viability assessment revealed that
the secretome of BMSCs and HUCPVCs, in the form of CM, was able to induce their survival. Moreover, immunocytochemical
experiments showed that CM from both MSCs was capable of inducing neuronal differentiation of SH-SY5Y cells. Finally, neurite
lengths assessment and quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) analysis demonstrated
that CM from BMSCs and HUCPVCs differently induced neurite outgrowth and mRNA levels of neuronal markers exhibited by
SH-SY5Y cells. Overall, our results show that the secretome of both BMSCs and HUCPVCs was capable of supporting SH-SY5Y
cells survival and promoting their differentiation towards a neuronal phenotype.
1. Introduction
Central nervous system (CNS) neurological disorders/inju-
ries often pose a major challenge for treatment due to the
limited capability of CNS to self-renew and to regenerate [1].
These CNS features have prompted the search for new ther-
apies, such as those using mesenchymal stem cells (MSCs).
MSCs have been defined as multipotent cells which are
capable of self-renewal [2]. Additionally, they are known to
adhere to tissue culture flasks and to display the presence of
MSCs surface markers (CD105, CD73, and CD90), as well as
the lack of hematopoietic MSCs cell surface markers (CD45,
CD34, CD14 or CD11b, CD79a or CD19 and human leukocyte
antigen DR) [2, 3]. Current sources of MSCs include bone
marrow, adipose tissue, dental pulp, placenta, amniotic fluid,
umbilical cord blood, umbilical cord Wharton’s jelly, liver,
lung, and spleen [3, 4].
MSCs isolated from different sources have been proposed
for CNS related applications. Indeed, MSCs transplantation
has shown to have a therapeutic effect in animal models
of ischemia [5, 6], spinal cord injury (SCI) [7, 8], and
Parkinson’s disease (PD) [9, 10]. The underlying mechanisms
by which the MSCs transplantation mediates the beneficial
outcomes remain to be elucidated. Although the putative
MSCs differentiation into neuronal lineages has been pur-
posed as the major contributor for CNS regeneration in
animal models of neurodegenerative diseases [11–15], MSCs
differentiation into full functional neuronal lineages remains
to be clarified [16–18]. In contrast, robust data indicates
that CNS tissue restorative effects are mediated by MSCs
secretome, that is, the panel of bioactive factors and vesicles,
with neuroregulatory properties, released by these cells to the
extracellular environment [10, 19–42].
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For instance, we have demonstrated that human BMSCs
secretome promotes cell survival and increases cell viability
of rat postnatal hippocampal neurons and cortical glial cells
[19]. Nakano et al. also showed that the secretome of BMSCs
cultured in the supernatant of ischemic brain extracts was
able to increase neuronal survival and neurite outgrowth
of postnatal rat hippocampal neurons, through apoptosis
suppressionmechanisms [20].These findings were correlated
with the expression and secretion of IGF-1 (insulin-like
growth factor 1), HGF (hepatocyte growth factor), VEGF
(vascular endothelial growth factor), and TGF 𝛽1 (trans-
forming growth factor beta 1) by the BMSCs [20]. This was
further confirmed by other studies in which, upon being
cultured with extracts from ischemic and traumatic brain,
BMSCs altered its gene expression profile when compared
with uninjured control brain extracts [21, 22]. Moreover,
significant improvements in functional recovery were also
described in in vivo models of ischemia, upon intravenous
injection of BMSCs [23–25]. In these studies, improvements
in neurologic function were accompanied by a reduction
of infarct size and/or with an increase in endogenous cell
proliferation and a reduction of apoptosis. These neuropro-
tective and neurorecovery effects have thus been attributed
to BMSCs secretion of interleukin-6 (IL-6) neurotrophic
and anti-inflammatory cytokine as well as of growth factors
(GFs) such as nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), glial cell-derived neurotrophic
factor (GDNF), VEGF, TGF 𝛽1, IGF-1, insulin-like growth
factor 2 (IGF 2), epidermal growth factor (EGF), and basic
fibroblast growth factor (bFGF).
Similar findings were also reported in in vitro [26–
29] and in vivo [30–32] models of spinal cord injury. For
instance, Fu¨hrman et al. [28] and Gu et al. [29] reported
that coculture of BMSCs with dorsal root ganglia (DRG)
explants and neurons significantly enhanced neuronal cell
survival and neurite outgrowth, through the secretion of
NGF, BDNF, bFGF, and CNTF (ciliary neurotrophic factor),
HGF, SDF-1 (stromal cell-derived factor 1), VEGF, EGF, NT-3
(neurotrophin-3), and NT-4 (neurotrophin 4) GFs, as well as
IL-1 (interleukin-1), IL-6, and IL-8 (interleukin-8) cytokines.
This expression pattern is in accordance with data published
by others upon BMSCs transplantation in animal models
of SCI [30–32]. On the other hand, several authors have
also reported that BMSCs expression of BDNF, GDNF, EGF,
bFGF, VEGF, HGF, SDF-1, and NT-3 could be correlated
with dopaminergic (DAergic) neurons protection against 6-
hydroxydopamine (6-OHDA)neurotoxin both in in vitro and
in vivomodels of PD [33–35].
Similarly, the secretome of MSCs isolated from the
Wharton’s jelly of the umbilical cord (WJ-MSCs) also dis-
closed some interesting properties for CNS regenerative
medicine. For instance, Ribeiro et al. [36] and Fraga et
al. [37] revealed that the secretome of mesenchymal pro-
genitors isolated from the Wharton’s jelly of the umbilical
cord increased neuronal cell viability and cell densities.
These effects were attributed to the expression of NGF and
the vesicular fraction of the secretome, respectively, which
contained proteins typically involved in neuroprotection.
Several studies also revealed that the expression of neuro-
protective, neurogenic, and angiogenic GFs as well as of
growth-associated cytokines, like BDNF, GDNF, bFGF, G-
CSF (granulocyte colony-stimulating factor), SDF-1, PDGF-
AA (platelet-derived growth factor AA), angiopoietin-2,
VEGF receptor 3 (VEGF-R3), CXCL-16 (chemokine lig-
and 16), and NAP-2 (neutrophil-activating protein-2), could
be correlated with WJ-MSCs beneficial outcomes towards
ischemic stroke in rats [38–40]. On the other hand, Yang et al.
[41] and Hu et al. [42] linked the improvement of locomotor
function, the neuroprotection, and the axon regeneration in
a rat SCImodel with theWJ-MSCs secretion of NT-3, GDNF,
bFGF, VEGF-R3, NAP-52 (neutrophil-activating protein-52),
and GITR (glucocorticoid-induced tumor necrosis factor
receptor). Finally, Weiss et al. [10] showed that WJ-MSCs
transplantation could also ameliorate the condition of a hemi-
Parkinsonian rat model through the secretion of GDNF
and FGF 20 (fibroblast growth factor 20) DAergic trophic
factors.
Despite all these studies, there are few reports where
the effects of the secretome of MSCs, isolated from different
sources, on neuronal cell populations are directly compared.
Therefore, in the present study we aimed to determine to
which extent the secretome of MSCs isolated from the bone
marrow and the connective tissue surrounding umbilical
cord vessels affected the survival and differentiation of a
human neuroblastoma cell line. Our results show that the
secretome of BMSCs and HUCPVCs, in the form of CM, is
able per se to induce SH-SY5Y cells survival, differentiation
into neuron-like cells, and neurite outgrowth. Moreover, the
secretome of BMSCs and HUCPVCs, collected at different
time points, was capable of increasing SH-SY5Y neuronal
differentiation at the same extent as the retinoic acid (RA),
which is commonly used to differentiate SH-SY5Y cells [43].
Finally, CM from BMSCs and HUCPVCs displayed different
temporal profiles regarding stimulation of neurite outgrowth
and the gene expression of neuronal markers exhibited by
SH-SY5Y cells.
2. Materials and Methods
2.1. Cell Culture
2.1.1. Bone Marrow Tissue Derived Stem Cells. BMSCs were
acquired from PROMOCELL (Heidelberg, Germany). Cells
were thawed and expanded according to the protocol pre-
viously described by Silva et al. [44]. Briefly, BMSCs were
cultured in 𝛼-MEM (GIBCO, Grand Island, NY, USA)
supplemented with sodium bicarbonate (NaHCO
3
, MERCK,
USA), 10% of fetal bovine serum (FBS, BIOCHROM AG,
UK), and 1% of penicillin-streptomycin antibiotic (GIBCO).
Confluent cells were trypsinised, plated in new T75 tissue
culture flasks (NUNC, Denmark), at a density of 4.000
cells/cm2, and incubated at 37∘C in a 5% humidified CO
2
atmosphere. The culture medium was changed every two to
three days. BMSCs were used for experiments during passage
6 (P6).
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Figure 1:Metabolic viability (MTS test) of SH-SY5Y cells seven days
after incubation with BMSCs and HUCPVCs CM. Results revealed
that, for all CM tested conditions, the secretome of both MSCs
populations is able to support neuronal-like cell viability without
the use of any other exogenous growth factors. The differences
observed towards RA-differentiated cells (𝑃 < 0.05) are considered
to be natural as these cultures were supplemented with 1% of FBS.
Concerning statistical differences among time points, BMSCs CM
24 h promoted a significant increase in SH-SY5Y cells viability when
compared with theHUCPVCsCM24 h group (𝑃 < 0.01) (values are
shown asmean± SEM, 𝑛 = 3). Symbols correspondence to statistical
signification: (1) ∗ refers to comparisons between RA-differentiated
cells andMSCsCM; (2) # regards the correlation betweenMSCsCM
from the same time point ( ##𝑃 < 0.01, ∗𝑃 < 0.05).
2.1.2. Human Umbilical Cord Perivascular Cells. HUCPVCs
were kindly provided by Professor J. E. Davies (University
of Toronto, Canada). Cells isolation from umbilical cord
was performed according to the procedures described by
Sarugaser and coworkers [45]. Expansion of cells was per-
formed according to the protocol described above for BMSCs.
HUCPVCs were used for experiments during P6.
2.1.3. Human Neuroblastoma Cell Line. SH-SY5Y cells were
cultured following the methods previously published by
Lopes et al. [46]. Briefly, cells were thawed and grown in
T75 flasks (NUNC) containing Dulbecco’s modified Eagles
medium nutrient mixture F12 (DMEM/F-12, PAA, LAB-
CLINICS, M, Spain), to which were added 1% of gluta-
max (GIBCO), 10% of FBS (BIOCHROM AG), and 1% of
kanamycin sulfate (GIBCO). Confluent cells were trypsinized
and plated at a density of 42.105 cells/cm2 in 13mm
glass coverslips, double precoated with both poly-D-lysine
(SIGMA-ALDRICH, St. Louis,MO,USA) andpig skin gelatin
(SIGMA-ALDRICH), inserted in 24-well plates (NUNC) for
cell metabolic viability, immunocytochemical, and neurite
outgrowth assays. For analysis of SH-SY5Y cells gene expres-
sion regarding several neuronal markers, cells were plated
in 6-well plates (NUNC) at a density of 42.105 cells/cm2.
Afterwards, cells were incubated with the same medium
described above in a 5% humidified CO
2
atmosphere at 37∘C
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Figure 2: Cell densities forMAP-2 positive cells presenting neurites
seven days after incubation with BMSCs and HUCPVCs CM.
Immunocytochemistry assessment (using Cell-P software and 20x
magnification micrographs) revealed that all CM tested conditions
presented similar percentages of MAP-2 positive cells when com-
pared to RA-differentiated cells, the positive control for SH-SY5Y
differentiation (𝑃 > 0.05). The later effect was more noticeable
for the BMSCs CM 24 h. Therefore, these results show that the
secretome of both BMSCs andHUCPVCs is capable of inducing SH-
SY5Y cells differentiation into neuronal-like cells (values are shown
as mean ± SEM, 𝑛 = 5, and statistical significance was defined as
𝑃 < 0.05).
for 24 h, afterwhichmediawere changed and the experiments
were performed as described below. SH-SY5Y cells were used
for experiments between passages 11 and 15.
2.1.4. Conditioned Media Collection and Experiments. CM
was collected from P6 BMSCs and HUCPVCs as previously
reported by Fraga et al. [37]. Shortly, cells were plated at a
density of 4.000 cells/cm2 and allowed to grow for 3 days in a
5%humidifiedCO
2
atmosphere at 37∘C.Culturemediumwas
then renewed and collected 24 h and 96 h thereafter (cell cul-
ture was not renewed or added during this time period). Col-
lected CM were frozen and thawed only in the day of experi-
ments. For CM collection, DMEM/F-12 media supplemented
with 1% of glutamax and 1% of kanamycin sulfate were used.
For differentiation assays, SH-SY5Y cells were incubated
with BMSCs or HUCPVCs CM and respective positive
control for neuronal differentiation (SH-SY5Y cells were cul-
tured with DMEM/F-12 (PAA, LABCLINICS) supplemented
with 1% of glutamax (GIBCO), 1% of FBS (BIOCHROM
AG), 1% of kanamycin sulfate (GIBCO), and 10 𝜇M of
RA (SIGMA-ALDRICH)). An additional group, SH-SY5Y
proliferative/undifferentiated cells, was also carried out (see
Supplementary Data in Supplementary Material available
online at http://dx.doi.org/10.1155/2014/438352). The culture
mediumwas changed every day for 7 days, in the end ofwhich
cellmetabolic viability, differentiation, and neurite outgrowth
were assessed in parallel with all other experimental condi-
tions.
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Figure 3: Fluorescence microscopy micrographs of SH-SY5Y cells immunostained with MAP-2 seven days after incubation with RA (a),
BMSCs CM (24 h, 96 h: (b), (d)), andHUCPVCs CM (24 h, 96 h: (c), (e)). As it can be observed, the secretome of both BMSCs andHUCPVCs
was able to induce SH-SY5Y cells differentiation into neuronal-like cells.
2.2. Cell Viability Assessment. Cell metabolic viability was
assessed by the MTS test. The MTS [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] test (PROMEGA, Madison, WI, USA) is a cell
viability assay based on the bioreduction of the substrate
(MTS) to a brown formazan product. Cell culture coverslips
(𝑛 = 3 replicates) were set in culture medium containing
MTS in a 5 : 1 ratio and incubated at 37∘Cwith 5% humidified
CO
2
atmosphere.Three hours after incubation, 100𝜇L of each
sample was transferred to 96-well plates (𝑛 = 3 replicates)
and optical density (OD) was measured at a 490 nm.
2.3. Immunocytochemistry. Cells were cultured in double pre-
coated coverslips (𝑛 = 5), fixed with 4% paraformaldehyde
(MERCK, USA), and incubated for 30min at room tem-
perature (RT). After incubation, cells were permeabilised
by incubation with 0.3% triton X-100 (MERCK)/PBS 1x
(GIBCO).Membrane receptors were then blocked for 60min
(RT) with 10% FBS (BIOCHROMAG)/PBS. Afterwards, cells
were incubated (60min) with mouse anti-rat microtubule-
associated protein 2 (MAP-2) antibody (SIGMA-ALDRICH)
to detect mature SH-SY5Y neurons. Cells were washed there-
after with 0.5% FBS/PBS solution and incubated for 60min
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Figure 4: Quantitative analysis of SH-SY5Y neurite outgrowth
seven days after incubation with BMSCs and HUCPVCs CM.
Quantification of neurite lengths showed that for all CM conditions,
with exception of SH-SY5Y cells cultured with BMSCs CM 96 h,
the CM of BMSCs and HUCPVCs induced a neurite outgrowth and
length very similar to the RA-differentiated cells group (𝑃 > 0.05).
The decrease in the mean neurite length observed in the BMSCs
CM 96 h group (𝑃 < 0.05) suggests that the neuronal differentiation
inducement of SH-SY5Y cells may be associated with the temporal
profile of MSCs CM collection (values are shown as mean ± SEM,
𝑛 = 5, ∗𝑃 < 0.05).
(RT) with Alexa Fluor 488 goat anti-mouse immunoglobulin
G. Finally, samples were incubated for 5min with DAPI
(4󸀠,6-diamidino-2-phenylindole dihydrochloride), to stain
cells nuclei (THERMO SCIENTIFIC, Rockford, USA), and
observed under an OLYMPUS IX-81 fluorescence micro-
scope (OLYMPUS, Germany).
2.4. Cell Counts. For cell counts, five representative fields of
each coverslip condition (𝑛 = 5 replicates) were selected
with 20x magnification and analyzed using Cell-P software
(OLYMPUS, Germany). In addition, according to the liter-
ature, MAP-2 positive cells with one or more neurites were
counted as differentiated cells [47].
2.5. Neurite Lengths Assessment. For neurite lengths assess-
ment in SH-SY5Y neuron-like cells, multiple representative
fields of cells morphology stained with MAP-2 labeling were
photographed with an IX-81 OLYMPUS fluorescence micro-
scope (OLYMPUS, Germany) fitted to a DP-711 digital cam-
era (OLYMPUS, Germany). Captured images were labeled
with a scale according to the correspondent microscope
magnification (40x). The images scale was used to convert
pixels units into micrometers (𝜇m), using for this purpose
the NIH Image J (Rasband WS, Image J, NIH), version 1.41.
In addition, the channels were extracted to grey scale and the
length of 5 to 10 neurites per field was traced and measured,
thereafter, from the distal end of neuron growth-cone, using
the neurite tracer plugin of NIH Image [48, 49].
2.6. Quantitative Real-Time RT-PCR. Total cellular ribonu-
cleic acid (RNA) was extracted from SH-SY5Y differentiated
cells with RA or MSCs CM (𝑛 = 3 replicates), using Trizol
reagent (APPLIED BIOSYSTEMS, Life Technologies, CA,
USA) for cell lysis and chloroform (MERCK)/isopropanol
(THERMO SCIENTIFIC) for RNA isolation. The amount of
RNA extracted and its purity were determined by measuring
OD at 260 nm and 280 nm in ND-1000 spectrophotometer
(ALFAGENE, PT). RNA was then treated with ribonuclease
(RNAse) free desoxirribonuclease (DNAse, THERMO SCI-
ENTIFIC) and 1 𝜇g of total RNA was reverse-transcribed
using Superscript kit (BIO-RAD, CA, USA) to obtain com-
plementary deoxyribonucleic acid (cDNA). After obtaining
cDNA, 1 𝜇g of cDNA per reaction was amplified by quantita-
tive real-time PCR in a CFX96 detection system (BIO-RAD)
by means of SSOfast Evagreen supermix (BIO-RAD) and
the primers sequences (concentration of 1𝜇M) previously
described, using an annealing temperature of 60∘C [50]. Each
aliquot of cDNAwas subjected to 40 PCR amplification cycles
(94∘C for 20 s, primer annealing at 60∘C for 30 s, extension
at 72∘C for 40 s). Primers sequences used corresponded to
several genes, namely, synaptophysin, 𝛽III tubulin, MAP-
2, DRD2 (dopamine receptor D2), and DAT (dopamine
transporter). The expression levels of neuronal markers were
determined using the previously reported 2−ΔΔ𝐶
𝑇
(2-(Delta
Delta 𝐶(𝑇)) method [51].
2.7. Statistical Analysis. Statistical evaluation was performed
using one-way ANOVA followed by Bonferroni’s post hoc
test to assess statistical correlation between retinoic acid-
differentiated cells (RA-differentiated cells) and conditioned
media groups (for statistical evaluation, 3 replicates of each
sample were used to perform the MTS test and RT-PCR,
whereas five replicates were used to assess immunocyto-
chemical and neurite outgrowth data (𝑛 = 3/𝑛 = 5; RA-
differentiated cells/CM time point ±SEM). These statistical
tests were complemented with student’s 𝑡-test to determine
statistical correlation between RA and conditioned media
groups (𝑛 = 3/𝑛 = 5; RA-differentiated cells/CM time point ±
SEM)) or between conditioned media groups corresponding
to the same time point (𝑛 = 3/𝑛 = 5; CM time point ± SEM).
Statistical significance was defined as 𝑃 < 0.05 for a 95%
confidence interval.
3. Results and Discussion
In the present study we aimed to determine and compare
how the secretome of two MSCs populations, derived from
either the bone marrow or the Wharton Jelly surrounding
umbilical cord vessels, could impact the viability and neu-
ronal differentiation of a human neuroblastoma cell line. For
this purpose, SH-SY5Y cells incubated with a combination of
lowpercentage of FBS andRA treatmentwere used as positive
control of SH-SY5Y cells differentiation (RA-differentiated
cells). Results revealed that cells incubated with both BMSCs
and HUCPVCs CM had similar levels of metabolic viability
after 7 days of culture (Figure 1). However, the values were
significantly lower (𝑃 < 0.05) than those obtained for
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Figure 5: Representative micrographs (magnification: 40x) used to quantify neurite outgrowth in SH-SY5Y cells seven days after incubation
with RA (a), BMSCs CM (24 h, 96 h: (b), (d)), and HUCPVCs CM (24 h, 96 h: (c), (e)) through the use of neurite tracer plugin from Image J.
control samples. These differences were within the expected
as control cultures were incubated with 1% of FBS, which
can increase their metabolic viability. Of note is the fact
that SH-SY5Y cells were not able to survive for more than 5
days of in vitro culture when incubated in plain neurobasal
media, without the addition of any other supplements (CM
control; data not shown). This fact is a strong indicator that,
per se, the secretome of both MSCs populations is able to
support neuronal-like cell viability, without the use of any
other exogenous growth factors.
Following this initial cell viability assay, an analysis
on the differentiation of SH-SY5Y cells incubated with
BMSCs/HUCPVCs CM or RA was performed by determin-
ing the percentage of cells positive for the neuronal marker
MAP-2 that displayed one or more neurites (Figure 2). This
criterion was established according to what was previously
described by Encinas et al. [47]. Results revealed that all CM
incubated groups had similar percentages of differentiated
SH-SY5Y cells when compared to the positive control for cell
differentiation (RA-differentiated cells, 𝑃 > 0.05) (Figure 2
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Figure 6: Variation of neuronalmarkers seven days after incubation
with BMSCs and HUCPVCs CM. Levels of mRNA for different
neuronal markers were quantified by quantitative real-time RT-
PCR and normalized to both undifferentiated/proliferative cells
(reference level: 1) and HBMS housekeeping gene. Quantification
of neuronal markers expression revealed that BMSCs CM 24 h
and 96 h displayed a significant increase in the SH-SY5Y cells
expression of DRD2 gene when compared to RA-differentiated cells
(𝑃 < 0.05). However, BMSCs CM 96 h simultaneously induced
a decrease in synaptophysin in comparison with RA-differentiated
cells (𝑃 < 0.05). On the other hand, for all the neuronal markers
studied, no statistically significant differences were found between
HUCPVCs CM 24 h and RA groups (𝑃 > 0.05). Yet, HUCPVCs
CM 96 h significantly elevated mRNA levels of DRD2 and DAT
genes when compared with both BMSCs 96 h (𝑃 < 0.05; 𝑃 <
0.01) and RA-differentiated cells (𝑃 < 0.01; 𝑃 < 0.05). The later
results suggest that HUCPVCs CM 96 h is inducing SH-SY5Y cells
towards the DAergic phenotype. In addition, differences between
BMSCs and HUCPVCs from the same time point indicate that
different tissue derived MSCs secretome have distinct effects in SH-
SY5Y cells differentiation with respect to neuronal phenotype. For
all the other neuronal markers studied, no significant statistical
differences were observed between all CM tested conditions and
RA-differentiated cells (𝑃 > 0.05), which strongly indicates that the
CM from BMSCs and HUCPVCs are capable of inducing SH-SY5Y
cells neuronal differentiation. Moreover, the different expression
pattern of neuronal markers exhibited by SH-SY5Y cells among
CM time points of collection indicates that the effects mediated
by MSCs secretome in SH-SY5Y cells differentiation is related with
the temporal profile of CM collection (values are shown as mean ±
SEM, 𝑛 = 3). Symbols correspondence to statistical signification: (1)
∗ refers to comparisons between RA-differentiated cells and MSCs
CM and (2) # regards the correlation between MSCs CM from the
same time point ( ∗∗/##𝑃 < 0.01, ∗/#𝑃 < 0.05).
and Figures 3(a) to 3(e)). This effect was more noticeable for
the BMSCs CM 24 h (Figure 2 and Figure 3(b)). Thus, from
the data obtained, it is possible to state that the secretome of
both BMSCs and HUCPVCs is capable of inducing SH-SY5Y
cells neuronal differentiation.
In order to further understand the role of the CM of
HUCPVCs and BMSCs on SH-SY5Y neuronal differentia-
tion, a quantitative analysis of neurite lengths was carried out
(Figure 4). As it can be observed, BMSCs CM 24 h as well as
HUCPVCsCM24 h and 96 h had very similar results to those
of the RA-differentiated cells group (𝑃 > 0.05) (Figure 4 and
Figures 5(a) to 5(c) and 5(e)), which is a strong indicator of
the differentiation effects of the secretomeof bothBMSCs and
HUCPVCs. Finally, the decrease in the mean neurite length
observed in the BMSCs CM 96 h group (𝑃 < 0.05) (Figure 4
and Figures 5(a) and 5(d)) may be related with the half-life of
neurotrophic factors present in the CM at the point of their
collection [19, 36, 37].
To confirm SH-SY5Y cells differentiation towards
neuronal phenotype, seven days after incubation with CM
from BMSCs and HUCVCs, mRNA expression of several
neuronal specific markers was assessed by quantitative RT-
PCR. According to the literature, mRNA levels of dopamine
transporter and receptor D2 as well as levels of vesicle
proteins (e.g., synaptophysin), neuronal specific cytoskeletal
proteins (e.g., MAP-2), and globular proteins (e.g., 𝛽III
tubulin) were found increased in SH-SY5Y cells upon differ-
entiation with RA [50, 52]. As it can be observed in Figure 6,
the mRNA level of DRD2 was significantly increased in
SH-SY5Y cells differentiated with BMSCs CM 24 h when
compared to RA-differentiated cells (𝑃 < 0.05). Similarly,
DRD2 gene expression was significantly elevated in SH-SY5Y
cells differentiated with BMSCs CM 96 h when compared
to RA-differentiated cells (𝑃 < 0.05). On the other hand, for
all the neuronal markers studied, no statistically significant
differences for SH-SY5Y cells gene expression were found
between HUCPVCs CM 24 h and RA groups (𝑃 > 0.05).
Interestingly, SH-SY5Y cells differentiation with HUCPVCs
CM 96 h resulted in a significant increase in DRD2 and DAT
genes expression in comparison with RA-differentiated cells
(𝑃 < 0.01, 𝑃 < 0.05). As DAT is a gene expressed only by
DAergic neurons [53], this result suggests that GFs present in
HUCPVCs CM 96 hmay be inducing SH-SY5Y cells towards
the DAergic phenotype. Indeed, it has been reported that
SH-SY5Y cells differentiate into the cholinergic, adrenergic,
or DAergic phenotype depending on media conditions [52].
In addition, the different SH-SY5Y cells expression pattern
observed between HUCPVCs CM 24 h and HUCPVCs 96 h
further reinforces the hypothesis that different temporal pro-
files of CM collection have distinct effects on SH-SY5Y cells
differentiation. For all the other neuronal markers studied,
no significant differences were found among the different
tested CM conditions and RA groups (𝑃 > 0.05). These
results further reinforce that the secretome of both BMSCs
and HUCPVCs induces neuronal differentiation of SH-SY5Y
cells. RT-PCR results also revealed differences regarding
mRNA levels of DRD2 and DAT genes between BMSCs and
HUCPVCs, collected at the same time point (96 h). Indeed,
SH-SY5Y cells differentiated with HUCPVCs CM 96 h
exhibited significant greater expression of both DRD2 and
DAT genes than cells differentiated with BMSCs CM 96 h
(𝑃 < 0.05,𝑃 < 0.01).The later result suggests not only that the
different secretome composition of different tissue derived
MSCs induces SH-SY5Y cells differentiation into different
neuronal phenotypes but also that the effects mediated by the
secretome of MSCs in neuronal differentiation are associated
with the temporal profile of CM collection [19, 36, 37].
4. Conclusions
The present study has shown that the secretome of both
BMSCs and HUCPVCs was capable of supporting SH-SY5Y
8 Stem Cells International
cell survival, while promoting their differentiation towards a
neuronal phenotype. Furthermore, it was also observed that
the secretome collected from both MSCs populations may
induce SH-SY5Y cells differentiation into different neuronal
phenotypes, which is an indicator of possible differences
within the secretome of the two cell populations. Therefore,
future studies should not only provide full characterization
of factors secreted by MSCs derived from different microen-
vironments/sources but also assess the impact that different
temporal profile of secretome collection can hold towards
different CNS pathologies/injuries. Additionally the effects of
cell passaging on MSCs secretome should also be assessed.
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